Weekly Roundup for March 22, 2024: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
More study is needed regarding the safety of sedative-hypnotic medications during pregnancy.
Dr. Marlene Freeman recently shared her insights on Psychiatric Medications and Considerations for Individuals Across Pregnancy, the Postpartum, and Reproductive Years with the National Alliance on Mental Illness on March 7, 2024.
In this large cohort study analyzing data from publicly insured Medicaid beneficiaries, the overall risk of malformations was lower with buprenorphine than with methadone.
Women who experienced depression during pregnancy were about four times as likely to experience PPD compared to women with no depression during pregnancy, with greater risk associated with depression during the first and third trimesters.
To better care for pregnant and postpartum mothers with ADHD, clinicians should understand the unique facets of ADHD in women, how symptoms change during pregnancy and the postpartum period, and how to help new parents make decisions around medication use and ADHD symptom management.
Every week we review the most recent publications in women’s mental health.
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
Every week we review the most recent publications in women’s mental health.
Dexmedetomidine, an α2-adrenergic receptor agonist, shows promise in preventing postpartum depression, reducing symptoms and improving sleep and pain control in women with prenatal depression.